Neurology

doi: 10.25005/2074-0581-2020-22-1-56-60
ASSESSMENT OF COGNITIVE STATUS IN PATIENTS WITH AKINETIC-RIGID AND TREMOR-DOMINANT PARKINSON’S DISEASE

N.A. Zaripov, M.T. Ganieva

Department of Neurology and Basics of Medical Genetics, Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan

Objective: To study cognitive changes in patients with akinetic-rigid and tremor-dominant Parkinson’s disease (PD).

Methods: From January to May 2019 were examined and responded 32 patients with akinetic-rigid (n=15; 46.9%) and tremor-dominant (n=17; 53.1%) PD. The average age of the patients was 66.5±3.7 years. All patients of PD before and after receiving appropriate therapy were responded using the MMSE (Mini-Mental State Examination) scale to detect the possible cognitive dysfunctions. The study of cognitive functions in patients was conducted before the start of therapy, as well as 3 months after treatment.

Results: At the admission, cognitive disorders were more significant in akinetic-rigid PD than in a tremor-dominant PD. After 3 months of appropriate therapy, cognitive dysfunction rates in patients with akinetic-rigid PD improved significantly (p<0.001) in compare to tremor-dominant PD (p<0.05).

Conclusions: Using the MMSE scale helps to detect and determine the severity of cognitive changes in a timely manner and the risk of further development of dementia in patients with PD, that allows to start corrective activities in time. Timely detection and appropriate approach to the treatment of the underlying disease and the correction of cognitive impairment significantly improves the quality of life of patients themselves, contributes reducing economic costs.

Keywords: Parkinson’s disease, cognitive disorders, akinetic-rigid and tremor-dominant Parkinson’s disease, MMSE scale.

Download file:


References
  1. Gubanova EN, Fyodorova NV. Osobennosti klinicheskoy kartiny bolezni Parkinsona v rannikh stadiyakh. Oshibki diagnostiki raznykh form [Features of the clinical picture of Parkinson’s disease in the early stages. Diagnostic errors of various forms]. Nevrologiya, neyropsikhiatriya, psikhosomatika. 2013;2:58-63.
  2. Gimoyan LG, Silvanyan GG. Narushenie kognitivnykh funktsiy: aktual’nost’ problemy, faktory riska, vozmozhnosti profilaktiki i lecheniya [Cognitive impairment: the urgency of the problem, risk factors, the possibility of prevention and treatment.]. Arkhiv vnutrenney meditsiny. 2013;2:35-40.
  3. Tsoi KK, Chan JY, Hirai HW, Wong SY, Kwok TC. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(9):1450-8.
  4. Aralbaeva AD, Kamenova SU, Kuzhybaeva KK. Bolezn’ Parkinsona [Parkinson’s disease.]. Vestnik KazNMU. 2019;1:199-201.
  5. Mazurenko EV, Panomaryov VV, Sakovich RA. Kognitivnye narusheniya pri bolezni Parkinsona [Cognitive impairment in Parkinson’s disease]. Meditsinskie novosti. 2014;1:6-11.
  6. Stein J, Luppa M, Maier W, Wagner M, Wolfsgruber S, Scherer M, et al. Assessing cognitive changes in the elderly: reliable change indices for the Mini-Mental State Examination. Acta Psychiatr Scand. 2012;126(3):208-18.
  7. Mormile MEE, Langdon JL, Hunt TN. The role of gender in neuropsychological assessment in healthy adolescents. J Sport Rehabil. 2018;27(1):16-21.
  8. Yakovleva TV, Karakulova YuV, Demchuk ND. Kompleksnoe sravnitel’noe psikhometricheskoe testirovanie patsientov s bolezn’yu Parkinsona [Comprehensive comparative psychometric testing of patients with Parkinson’s disease]. Sovremennye problemy nauki i obrazovaniya. 2015;6:85.
  9. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896-912.
  10. Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson’s disease. Curr Opin Neurol. 2014;27(4):434-41.
  11. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord. 2013;28(3):311-8.
  12. Xicoy H, Peñuelas N, Vila M, Laguna A. Autophagic- and lysosomal-related biomarkers for Parkinson’s disease: Lights and shadows. Cells. 2019;8(11): pii: E1317. Available from: https://doi.org/10.3390/cells8111317.
  13. Atta NF, Galal A, El-Ads EH, Galal AE. Efficient electrochemical sensor based on gold nanoclusters/carbon ionic liquid crystal for sensitive determination of neurotransmitters and anti-Parkinson drugs. Adv Pharm Bull. 2020;10(1):46- 55.
  14. Wang CY, Chan L, Wu D, Chi WC, Yen CF, Liao HF, et al. Effect of cognitive disability and ambulation status on functioning in moderate-to-advanced Parkinson disease. Front Neurol. 2020;10:1360.
  15. Rutten S, Vriend C, Berendse HW, Van der Werf YD, van den Heuvel OA. Anxiety, depression and sleep disorders in Parkinson’s disease: a complex interaction between body and mind. Tijdschr Psychiatr. 2020;62(1):62-72.
  16. Cholerton B, Poston KL, Tian L, Quinn JF, Chung KA, Hiller AL, et al. Participant and study partner reported impact of cognition on functional activities in Parkinson’s disease. Mov Disord Clin Pract. 2019;7(1):61-9.
  17. Grimes D, Gordon J, Snelgrove B, Lim-Carter I, Fon E, Martin W, et al. Canadian guidelines on Parkinson’s disease. Can J Neurol Sci. 2012;39(4):1-30.
  18. Karaban IN. Levodopa/karbidopa prolongirovannogo vysvobozhdeniya v lechenii bolezni Parkinsona [Levodopa/extended release carbidopa in the treatment of Parkinson’s disease]. Mezhdunarodnyy nevrologicheskiy zhurnal. 2018;3:48-58.
  19. Ignatyeva OI, Chibiryakova EO. Osobennosti techeniya bolezni Parkinsona u muzhchin [Features of the course of Parkinson’s disease in men]. Ogaryov-Online. 2019;2:9.
  20. Lees AJ. Drugs for Parkinson’s disease. J Neurol Neurosurg Psychiat. 2015;11:607-765.

Authors informations:

Zaripov Nurali Abdurakibovich
PhD Student, Department of Neurology and Basics of Medical Genetics, Avicenna Tajik State Medical University
ORCID ID: 0000-0001-5494-1218
E-mail: nur.tj-94@mail.ru

Ganieva Manizha Temurovna
Candidate of Medical Sciences, Head of the Department of Neurology and Basics of Medical Genetics, Avicenna Tajik State Medical University
Researcher ID: E-4389-2019
ORCID ID: 0000-0001-5865-8954
E-mail: ganieva.manizha_79@mail.ru

Information about the source of support in the form of grants, equipment, and drugs

The authors did not receive financial support from manufacturers of medicines and medical equipment

Conflict of interest: No conflict

Address for correspondence:

Zaripov Nurali Abdurakibovich
PhD Student, Department of Neurology and Basics of Medical Genetics, Avicenna Tajik State Medical University

734003, Republic of Tajikistan, Dushanbe, Rudaki Ave., 139

Tel.: +992 (987) 329015

E-mail: nur.tj-94@mail.ru

Materials on the topic: